Here are the public health implications for these new research findings
Maryland Poison Control has reported a more than 1,500 percent increase in calls related to compounded GLP-1 medications since 2020
Medicare beneficiaries with obesity who meet certain criteria will have $50 copays for the medications
Based on the above evidence, short-term GLP-1RA/SGLT-2i combination therapy may be a better option for inadequately controlled, overweight or obese T2DM who are more likely to achieve weight loss goals
has divulged incretin analogues acting as dual agonists of gastric inhibitory polypeptide (GIPR) receptor/GLP-1 or GLP-1/glucagon receptor (GCGR) or triple agonists of GIPR/GLP-1/GCGR reported to be useful for the treatment of type 2 diabetes, dyslipidemia, obesity, metabolic syndrome, neurodegeneration, fibrosis and cardiovascular disorders
Other clues that your compounded prescription may not be legitimate: It does not require a prescription